Description

DIOVAN 160 MG (1X14)

Indications

DIOVAN (valsartan) 160 mg is primarily indicated for the treatment of hypertension (high blood pressure) in adults and children aged 6 years and older. It is also used to reduce the risk of cardiovascular events in patients with heart failure or those who have experienced a recent myocardial infarction (heart attack). By effectively lowering blood pressure, DIOVAN helps in preventing strokes, heart attacks, and kidney problems associated with hypertension.

Mechanism of Action

DIOVAN contains valsartan, which is an angiotensin II receptor blocker (ARB). It works by selectively blocking the action of angiotensin II, a potent vasoconstrictor that causes blood vessels to narrow and increases blood pressure. By inhibiting this receptor, valsartan promotes vasodilation (widening of blood vessels), leading to a decrease in blood pressure and reduced workload on the heart. This mechanism not only helps in managing hypertension but also provides protective effects on the heart and kidneys.

Pharmacological Properties

Valsartan is well-absorbed after oral administration, with peak plasma concentrations occurring within 2 to 4 hours. The bioavailability of valsartan is approximately 23%, and its absorption is not significantly affected by food. Valsartan is primarily metabolized by the liver, with a half-life of about 9 hours, allowing for once-daily dosing in most patients. The drug is excreted predominantly in the feces, with a small percentage eliminated through urine. Its pharmacological profile makes it a suitable option for long-term management of hypertension and heart failure.

Contraindications

DIOVAN is contraindicated in patients with a known hypersensitivity to valsartan or any of its components. It should not be used during pregnancy, particularly in the second and third trimesters, due to the risk of fetal harm. Additionally, DIOVAN is contraindicated in patients with severe hepatic impairment and those with a history of angioedema associated with previous treatment with an ACE inhibitor or ARB.

Side Effects

Common side effects associated with DIOVAN include dizziness, fatigue, headache, and abdominal pain. These effects are usually mild and transient. Serious side effects, although rare, may include hypotension (low blood pressure), renal impairment, hyperkalemia (high potassium levels), and angioedema (swelling of the deeper layers of the skin). Patients should be monitored for these adverse effects, especially during the initiation of therapy or when the dose is increased.

Dosage and Administration

The recommended starting dose of DIOVAN for adults with hypertension is 80 mg to 160 mg once daily. Depending on the patient’s response, the dose may be titrated up to a maximum of 320 mg per day. For pediatric patients aged 6 to 16 years, the dose is based on body weight, typically ranging from 1.3 mg/kg to a maximum of 160 mg once daily. DIOVAN can be taken with or without food, and patients are advised to take it at the same time each day to maintain consistent blood levels.

Interactions

DIOVAN may interact with other medications, which can alter its effectiveness or increase the risk of adverse effects. Notable interactions include potassium-sparing diuretics, potassium supplements, and nonsteroidal anti-inflammatory drugs (NSAIDs), which may increase the risk of hyperkalemia and renal impairment. It is essential for patients to inform their healthcare provider of all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before initiating therapy with DIOVAN, healthcare providers should assess renal function and serum potassium levels. Special caution should be exercised in patients with a history of renal artery stenosis, heart failure, or those who are volume-depleted. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment. Patients should be advised to maintain adequate hydration and to report any signs of hypotension, such as dizziness or fainting.

Clinical Studies

Clinical studies have demonstrated the efficacy of DIOVAN in lowering blood pressure and reducing cardiovascular risk. In a major clinical trial, valsartan was shown to significantly reduce systolic and diastolic blood pressure compared to placebo. Additionally, studies have indicated that valsartan improves outcomes in patients with heart failure, reducing hospitalizations and mortality rates. These findings support the use of DIOVAN as a first-line treatment option for hypertension and heart failure management.

Conclusion

DIOVAN 160 mg is a valuable medication for the management of hypertension and heart failure. Its mechanism of action as an angiotensin II receptor blocker provides effective blood pressure control and cardiovascular protection. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions. Regular monitoring and communication with healthcare providers are crucial for optimizing treatment outcomes and ensuring safe use of DIOVAN.